ABSK061 + ABSK043

ABSK061 + ABSK043 is a combination of two investigational small molecule drugs developed by Abbisko Therapeutics for the treatment of solid tumors with FGFR2/3 alterations. - **ABSK061** is a novel, orally bioavailable, highly potent and selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3). It was designed to minimize inhibition of FGFR1 in order to reduce side effects while maintaining efficacy against FGFR2/3-driven cancers. - **ABSK043** is an oral small molecule inhibitor targeting programmed death-ligand 1 (PD-L1), blocking the PD-1/PD-L1 interaction to enhance anti-tumor immune responses. Compared to antibody-based checkpoint inhibitors, it offers lower immunogenic risk and oral administration convenience. The combination is being evaluated in phase II clinical trials for metastatic or unresectable solid tumors harboring FGFR2/3 alterations—including non-small cell lung cancer, gastric/gastroesophageal junction carcinoma (HER2 negative), urothelial carcinoma, esophageal cancer, and other solid tumors—with or without chemotherapy. Both agents are also being explored for potential use in non-oncology indications such as achondroplasia[1][4][5][7].